Intellectual Property India Publishes Patent Application for 'Myconoside-Rich Extract From In Vitro Systems Of Plants Belonging To Genera Haberlea And Ramonda, Method Of Preparation, And Use As Chemo-, Radio- And Uv Protector' Filed by Innova Bm Ltd.

MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517054961 A) filed by Innova Bm Ltd., Sofia, Bulgaria, on June 6, for 'myconoside-rich extract from in vitro systems of plants belonging to genera haberlea and ramonda, method of preparation, and use as chemo-, radio- and uv protector.'

Inventor(s) include Tatarska, Petia Ivanova; Georgiev, Vasil Georgiev; and Pavlov, Atanas Ianov.

The application for the patent was published on July 4, under issue no. 27/2025.

According to the abstract released by the Intellectual Property India: "The present invention relates to a myconoside containing extract derived from in vitro systems of plants belonging to the family Gesneriaceae, in particular from the genera Haberlea and Ramonda, also including the species Haberlea rhodopensis Friv., Ramonda heldreichii (Boiss.) C.B. Clarke; Ramonda myconi (L.) Rchb.; Ramonda nathaliae Pancic & Petrovic, and Ramonda serbica Pancic, as well as from their hybrids, and a method of preparation thereof. Furthermore, the present invention also relates to the use of said extract in human and veterinary medicine, nutritional supplements and cosmetics as chemo-, radic- and UV protector. The described extract from in vitro systems of plants comprising, alone or in combination, Extract 1 of polyphenolic fraction, containing mainly flavone-C glycosides and phenylethanoids (PHE), and Extract 2 of fraction containing mainly phenylethanoids myconoside in particular myconoside and paucifloside especially, where Extract 1 comprises 0.1 to 55.0 wt % PHE and free phenols, sugars, organic-, fatty- and amino acids, sterols up to 100 wt%, while Extract 2 comprises 55.0 to 99.9 wt%of PHE (in particular, myconoside and paucifloside), and phenolic compounds, mono-, disaccharides or their residues up to 100 wt%. Extracts 1 and 2 obtained according to this invention mainly consist of RHE (in particular, myconoside and paucifloside) within a broad spectrum and quantitative limits. These compounds (in particular, myconoside) possess high biological activities, antioxidant, antimutagenic and anticlastogenic activities proven herein, therefore are suitable for use alone and in combination by metered blending, as well as to be conditioned by dilution, for the preparation of products used as natural chemo-, radio- and UV protectors with a controlled degree of protection. The latter are used in human and veterinary medicine, nutritional supplements and cosmetics for the prevention and treatment of harmful chemo-, radio- and UV effects."

The patent application was internationally filed on Dec. 20, 2022, under International application No.PCT/BG2022/000013.

Disclaimer: Curated by HT Syndication.